Treating malignant melanoma with lower doses of approved immunotherapy appears to result in improved results, while also reducing side effects. Investigators from the Karolinska Institutet in Stockholm, Sweden… read more.
Some blood pressure medications can make the skin extra prone to sunburn. A registry study from Lund University in Sweden shows a possible increased risk of basal cell… read more.
NICE (UK): Darolutamide with androgen deprivation therapy (ADT) can be used as an option to treat hormone-sensitive metastatic prostate cancer in adults, only if: i) docetaxel is not… read more.
VolitionRx Limited, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q® Cancer… read more.
Researchers report that an analysis of data from outpatient facilities in the New York State region revealed that 20-24% of breast cancers breast cancers diagnosed in an 11-year… read more.
AstraZeneca advances its ambition to redefine haematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and… read more.
Eli Lilly and Company announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the… read more.
Rigel Pharmaceuticals Inc. announced a peer-reviewed publication in the Journal of Hematology & Oncology of the final five-year data from the pivotal cohort of the Phase II registrational… read more.
Eli Lilly and Company announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking… read more.
Ono Pharmaceutical Co., Ltd. announced that they received supplemental approval in Japan for Braftovi (encorafenib) capsule in combination with cetuximab, an anti-human EGFR monoclonal antibody, and chemotherapy for… read more.
Adolescents and young adults (AYAs) with cancer have unique needs compared with other age groups. Access to palliative care among this age group remains challenging. New research published… read more.
Gilead Sciences Inc. announced the Phase III ASCENT-07 study investigating Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
